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editorialmanager.com/cgh.Working Together to Meet the Needs of
Patients With Inflammatory Bowel
DiseasesDear Editor:
We read with interest the article entitled “Coronavirus
Disease 2019 (COVID-19): What Should Gastroenterologists
and Their Patients Know?” by Ungaro et al.1 The authors
provided an informative and concise overview of COVID-19
through the lens of the gastroenterologist. Importantly, they
highlighted the paucity of data on the impact of COVID-19
on patients with gastrointestinal disease, including inflam-
matory bowel disease (IBD).1 Because COVID-19 is a novel
virus, it remains unclear how it will affect our patients,
particularly those on immunosuppressive medications. The
global gastroenterology community currently lacks the data
needed to answer the most pressing questions from our
patients: whether their disease places them at higher risk of
poor outcomes from COVID-19 and whether they should
stop or change current medications.
In an effort to answer these essential questions, we
developed the Surveillance Epidemiology of Coronavi-
rus) Under Research Exclusion (SECURE-IBD) registry in
collaboration with Dr Ryan Ungaro at the Icahn School of
Medicine at Mount Sinai (New York, NY). SECURE-IBD
(www.covidibd.org) is an international pediatric and
adult registry to monitor and report on outcomes of
COVID-19 occurring in IBD patients. SECURE-IBD was
developed in partnership with the Crohn’s & Colitis
Foundation, the International Organization for the Study
of IBD, the European Crohn’s and Colitis Organisation,
the North American Society for Pediatric Gastroenter-
ology, Hepatology, and Nutrition, the Asian Organization
for Crohn’s & Colitis, the Pan American Crohn’s and Co-
litis Organization, and several regional/national organi-
zations. The purpose of SECURE-IBD is to rapidly define
the impact of COVID-19 on patients with IBD, including
the impact of factors such as age, comorbidities, and
IBD treatments on COVID outcomes. SECURE-IBD is
committed to providing regular updates to the IBD
community regarding the number of reported cases and
outcomes, including data broken down by geographic
region and IBD treatment. We disseminate updates
through the project website, email, and Twitter.
The SECURE-IBD registry collects de-identified data, in
accordance with the Health Insurance Portability and
Accountability Act Safe Harbor De-Identification standards.2
The University of North Carolina–Chapel Hill Office forHuman Research Ethics has determined that storage and
analysis of de-identified data does not constitute human
subject research as defined under federal regulations [45
CFR 46.102 and 21 CFR 56.102] and does not require
institutional review board approval.3,4 We encourage IBD
clinicians worldwide to report all cases of COVID-19 in their
IBD patients, regardless of severity, after sufficient time has
passed to observe the disease course through resolution of
acute illness and/or death.
To date, the response to the SECURE-IBD registry
from the international gastroenterology community has
been truly extraordinary. As of April 24, 2020, more than
70,000 visitors from 145 countries have accessed the
SECURE-IBD website. Importantly, health care providers
worldwide have reported 704 cases to the registry. Many
users have provided valuable feedback that has allowed
us to improve our data collection approach.
To ensure that the registry generates the robust
data needed to inform the care of IBD patients, however, we
need to garner even broader participation. We write this
letter to implore all providers taking care of patients with
IBD to report cases of COVID-19 among their IBD patients
on our website. Reporting a case takes approximately 5
minutes, and will help us to better define the impact of
COVID-19 among our patient population.
Beyond IBD, we are in the process of helping leaders
across specialties to leverage this registry blueprint in
other disease states. Within the field of gastroenterology,
we have worked with cirrhosis and liver transplantation
(www.covidcirrhosis.org), eosinophilic gastrointestinal
disease, and celiac disease groups to leverage the
SECURE-IBD framework.5 Outside of gastroenterology,
we have supported investigators and organizations
studying related immune-mediated diseases (psoriasis,
juvenile idiopathic arthritis, rheumatoid arthritis, and
systemic lupus erythematosus) and hematologic condi-
tions including sickle cell disease, hematologic malig-
nancies, and solid malignancies. Now is the time to
collaborate across specialties to accelerate learning.
Through international cooperation, collaboration, and
communication, we will be able to optimize the care of
our patients during this unprecedented, worldwide
health crisis. We are truly all in this together!
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